Literature DB >> 17027219

[Optimal vancomycin serum level in Staphylococcus aureus infections?].

E Bingen1, P Mariani-Kurkdjian, B Nebbad.   

Abstract

Vancomycin is the cornerstone of therapy against methicillin-resistant Staphylococus aureus in both community and nosocomial-acquired infections. Because vancomycin is a concentration-independent or time-dependant antibiotic, most clinicians have abandoned the routine practice of determining peak serum concentrations to rely solely on monitoring serum concentrations. The so-called therapeutic range most often quoted for vancomycin was assessed for through serum concentrations of 5-10 mg/l. But prolonged exposure to serum concentration close to the MIC is associated with the emergence of resistance. More recent guidelines recommended vancomycin in concentrations of 15-20 mg/l for the treatment of severe Staphylococcus infections or in situations where vancomycin penetration is poor. However, because of the great variability of vancomycin MIC(S) (0,12-4 mg/l) of susceptible Staphylococcus strains, guidelines should recommend through serum concentrations of 5-10 times the MIC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027219     DOI: 10.1016/j.medmal.2006.07.016

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  2 in total

1.  Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function.

Authors:  O Rodriguez Colomo; F Álvarez Lerma; M I González Pérez; J-M Sirvent; M García Simón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-12       Impact factor: 3.267

2.  Incidence and risk factors of acute kidney injury associated with continuous intravenous high-dose vancomycin in critically ill patients: A retrospective cohort study.

Authors:  Guillaume Lacave; Vincent Caille; Fabrice Bruneel; Catherine Palette; Stéphane Legriel; David Grimaldi; Mathilde Eurin; Jean-Pierre Bedos
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.